a Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology , Westmead Hospital , Westmead , NSW , Australia.
b Sydney Centres for Thrombosis and Haemostasis , Westmead , Australia.
Platelets. 2018 Sep;29(6):622-627. doi: 10.1080/09537104.2018.1475636. Epub 2018 May 24.
Testing of platelet function comprises a crucial element of hemostasis assessment, particularly for investigations into bleeding and/or bruising. The Platelet Function Analyzer (PFA)-100 is the most utilized primary hemostasis-screening test system available, as recently remodeled/upgraded to the PFA-200. Internal quality control (IQC) and external quality assessment (EQA) (including proficiency testing) represent critical elements of ensuring test practice quality. Although true for all tests, IQC and EQA are logistically challenging for platelet function testing, inclusive of the PFA-100/200. We accordingly update our experience with novel yet feasible approaches to both IQC and EQA of PFA-100/200. Over the past 10 years, a total of 43 challenges have been tested, with most challenges designed to mimic moderate or severe primary hemostasis defects. The current report is restricted to the last four years and has also differentially assessed PFA-100 vs. PFA-200 EQA results to identify potential variance. Numerical results for closure times (CTs) and participant-supplied interpretive comments were analyzed. Reported CTs for each challenge were within limits of expectation, and good reproducibility was evidenced by repeated challenges. Coefficients of variation (CVs) for challenges, generally ranging from 15% to 25%, were similar or better than those obtained using native whole blood and consistent with past reports. Participant interpretations were generally consistent with test data and expectations. There was no evident difference in PFA-100 vs. PFA-200 EQA test results. The EQA material has also been successfully evaluated from the perspective of potential IQC. To conclude, IQC and EQA processes for the PFA-100/200 have been established that are highly reproducible, supporting the concept of EQA/IQC for platelet function testing, and also facilitating monitoring and improvement in its performance. In terms of EQA, PFA-100 and PFA-200 instruments appear to behave similarly.
血小板功能检测是止血评估的重要组成部分,特别是在出血和/或瘀伤的研究中。血小板功能分析仪(PFA)-100 是目前应用最广泛的原发性止血筛选检测系统,最近已进行了改造/升级,成为 PFA-200。内部质量控制(IQC)和外部质量评估(EQA)(包括能力验证)是确保测试实践质量的关键要素。虽然这对所有测试都适用,但 IQC 和 EQA 对于血小板功能测试,包括 PFA-100/200,在物流上具有挑战性。因此,我们更新了我们在 IQC 和 EQA 方面的经验,包括 PFA-100/200 的新型但可行的方法。在过去的 10 年中,共测试了 43 个挑战,其中大多数挑战旨在模拟中度或严重的原发性止血缺陷。本报告仅限于过去四年,并对 PFA-100 与 PFA-200 EQA 结果进行了差异评估,以确定潜在差异。分析了闭合时间(CT)的数值结果和参与者提供的解释性评论。每个挑战的报告 CT 都在预期范围内,并且通过重复挑战证明了良好的可重复性。挑战的变异系数(CV)通常在 15%到 25%之间,与使用天然全血获得的 CV 相似或更好,与过去的报告一致。参与者的解释通常与测试数据和预期一致。PFA-100 与 PFA-200 EQA 测试结果之间没有明显差异。从潜在 IQC 的角度来看,EQA 材料也已成功评估。总之,已经建立了 PFA-100/200 的 IQC 和 EQA 流程,这些流程具有高度的可重复性,支持血小板功能测试的 EQA/IQC 概念,并有助于监测和改善其性能。就 EQA 而言,PFA-100 和 PFA-200 仪器的表现似乎相似。